Leona Plum‐Mörschel

MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study

Phil Ambery, Victoria E R Parker, Michael Stümvoll et al. · The Lancet · 2018 · 295 citations

Obesity, Metabolic Syndrome, Medicine +7

Effect of the sodium glucose co‐transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus

Sue Sha, David Polidori, Tim Heise et al. · Diabetes Obesity and Metabolism · 2014 · 235 citations

Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non‐alcoholic fatty liver disease assessed by magnetic resonance imaging

Anne Flint, Grit Andersen, Paul Hockings et al. · Alimentary Pharmacology & Therapeutics · 2021 · 193 citations · Full text

Efficacy and safety of oral basal insulin versus subcutaneous insulin glargine in type 2 diabetes: a randomised, double-blind, phase 2 trial

Inge B. Halberg, Karsten Lyby, Karsten Wassermann et al. · The Lancet Diabetes & Endocrinology · 2019 · 166 citations

Subcutaneous Insulin Glargine, Diabetes Management, Insulin Management +6

Efficacy, Safety, and Mechanistic Insights of Cotadutide, a Dual Receptor Glucagon-Like Peptide-1 and Glucagon Agonist

Victoria E R Parker, Darren Robertson, Tao Wang et al. · The Journal of Clinical Endocrinology & Metabolism · 2019 · 115 citations · Full text